ANIP vs LLY: fair value comparison
ANI Pharmaceuticals, Inc. and Eli Lilly and Company · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our discount ranking. ANIP carries the stronger quality grade.
| ANIP | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $80.06 | $1,149.36 |
| 12-month range | $75.22–$94.06 | $862.86–$1,160.00 |
| Sector rank | #12 of 113 Healthcare | #11 of 113 Healthcare |
| Quality grade | C- | D |
| Leverage | Moderate | High |
| Margin trend | — | Expanding |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: ANIP fair value analysis · LLY fair value analysis